| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Robert C Doebele | Q88321795 |
| Aria Vaishnavi | Q114292507 | ||
| P2093 | author name string | Anh T Le | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma | Q24307374 | ||
| Comprehensive molecular characterization of human colon and rectal cancer | Q24630415 | ||
| Complex landscapes of somatic rearrangement in human breast cancer genomes | Q24631412 | ||
| Biological activity of the thyroid TRK-T3 oncogene requires signalling through Shc | Q24648398 | ||
| Grb2-associated binder-1 mediates phosphatidylinositol 3-kinase activation and the promotion of cell survival by nerve growth factor | Q24648537 | ||
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Crizotinib in anaplastic large-cell lymphoma | Q27851624 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. | Q27852601 | ||
| ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers. | Q27852699 | ||
| Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions | Q27853012 | ||
| Crizotinib in ROS1-rearranged non-small-cell lung cancer. | Q27853075 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain | Q28115087 | ||
| ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation | Q28217452 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma | Q28261572 | ||
| Oncogenes in solid human tumours | Q28279392 | ||
| A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences | Q28282360 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Identification and characterization of novel substrates of Trk receptors in developing neurons | Q28291632 | ||
| Ablation of TrkA function in the immune system causes B cell abnormalities | Q28509375 | ||
| Identification of a recurrent STRN/ALK fusion in thyroid carcinomas | Q28539208 | ||
| NTRK1 fusion in glioblastoma multiforme | Q28541127 | ||
| Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB | Q28589970 | ||
| Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death | Q28591473 | ||
| The trk proto-oncogene encodes a receptor for nerve growth factor | Q28609788 | ||
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 | ||
| Neurotrophins and their receptors: a convergence point for many signalling pathways | Q29616108 | ||
| Phosphatidylinositol-3-OH kinase as a direct target of Ras | Q29620177 | ||
| Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia | Q30959617 | ||
| IRS-1 and IRS-2 are recruited by TrkA receptor and oncogenic TRK-T1. | Q31809905 | ||
| An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression | Q33201368 | ||
| Role of STAT3 in in vitro transformation triggered by TRK oncogenes | Q33538057 | ||
| The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma | Q33751426 | ||
| Functional characterization of human cancer-derived TRKB mutations | Q33838325 | ||
| Kinase fusions are frequent in Spitz tumours and spitzoid melanomas | Q33854847 | ||
| TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor | Q33965019 | ||
| Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. | Q40787949 | ||
| Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia | Q42702851 | ||
| Functional characterization of NTRK1 mutations identified in melanoma | Q42800660 | ||
| A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation | Q43583292 | ||
| Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma | Q44846786 | ||
| Phenotype of cerebellar glutamatergic neurons is altered in stargazer mutant mice lacking brain-derived neurotrophic factor mRNA expression | Q45161814 | ||
| Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung | Q46738962 | ||
| Anchored multiplex PCR for targeted next-generation sequencing | Q48254505 | ||
| The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. | Q53403133 | ||
| The selective and inducible activation of endogenous PI 3-kinase in PC12 cells results in efficient NGF-mediated survival but defective neurite outgrowth | Q57903651 | ||
| A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia | Q59080605 | ||
| Expression of TRK-T1 oncogene induces differentiation of PC12 cells | Q70480006 | ||
| Phosphotyrosine residues in the nerve-growth-factor receptor (Trk-A). Their role in the activation of inositolphospholipid metabolism and protein kinase cascades in phaeochromocytoma (PC12) cells | Q70807017 | ||
| A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth | Q71614357 | ||
| Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors | Q74004423 | ||
| Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias | Q74545337 | ||
| Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses | Q34060592 | ||
| The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation | Q34105851 | ||
| Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma | Q34160782 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| The signaling adapters fibroblast growth factor receptor substrate 2 and 3 are activated by the thyroid TRK oncoproteins. | Q34177211 | ||
| Mechanisms of disease in hereditary sensory and autonomic neuropathies | Q34249122 | ||
| RET, ROS1 and ALK fusions in lung cancer | Q34253845 | ||
| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia | Q34314927 | ||
| Severe sensory and sympathetic neuropathies in mice carrying a disrupted Trk/NGF receptor gene. | Q34338664 | ||
| Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma | Q34354839 | ||
| Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease | Q34366768 | ||
| The landscape of kinase fusions in cancer | Q34437602 | ||
| Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study | Q34549193 | ||
| Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. | Q34576586 | ||
| Mutations in the TRKA/NGF receptor gene in patients with congenital insensitivity to pain with anhidrosis | Q34733805 | ||
| Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse | Q34754344 | ||
| Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma | Q34754714 | ||
| Role and relevance of TrkB mutations and expression in non-small cell lung cancer | Q34917434 | ||
| Rearrangements of NTRK1 gene in papillary thyroid carcinoma. | Q35010947 | ||
| New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing | Q35100996 | ||
| Neurotrophin receptors: a window into neuronal differentiation | Q35233385 | ||
| A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. | Q35791529 | ||
| Nerve growth factor receptors and signaling in breast cancer | Q35892752 | ||
| Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. | Q36429595 | ||
| The neurotrophic receptor TrkB: a drug target in anti-cancer therapy? | Q36433689 | ||
| Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies | Q36579186 | ||
| Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia | Q36591394 | ||
| The impact of translocations and gene fusions on cancer causation | Q36760027 | ||
| Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma | Q37188772 | ||
| The integrated landscape of driver genomic alterations in glioblastoma | Q37237987 | ||
| Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. | Q37259269 | ||
| ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer | Q37627018 | ||
| The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. | Q38981486 | ||
| Role of neurotrophins in neuropathic pain | Q40576520 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 25-34 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Cancer Discovery | Q15724440 |
| P1476 | title | TRKing down an old oncogene in a new era of targeted therapy | |
| P478 | volume | 5 |
| Q39002421 | A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2. |
| Q40173988 | A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors |
| Q57055324 | A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes |
| Q39022023 | A review of kinase fusions in melanocytic tumors |
| Q92911609 | A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA |
| Q64941546 | A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma. |
| Q93083546 | A zwitterionic near-infrared dye linked TrkC targeting agent for imaging metastatic breast cancer |
| Q28265615 | An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101 |
| Q91811059 | Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma |
| Q64079974 | Antitumor activity of larotrectinib in tumors harboring gene fusions: a short review on the current evidence |
| Q38989374 | Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview |
| Q41093124 | BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations |
| Q55424463 | Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. |
| Q46512789 | Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer |
| Q89861115 | Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers |
| Q90428742 | Breakthroughs and challenges in the management of tropomyosin receptor kinase fusion-positive tumors |
| Q91777772 | Cancer stem cells-driven tumor growth and immune escape: the Janus face of neurotrophins |
| Q90316280 | Challenges and Opportunities for Childhood Cancer Drug Development |
| Q46831652 | Clinical and molecular insights into adenoid cystic carcinoma: Neural crest‐like stemness as a target |
| Q55003763 | Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor. |
| Q95840207 | Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC) |
| Q59794416 | Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors |
| Q96341728 | Developing drugs for tissue agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine |
| Q90627871 | Distinct roles of PIK3CA in the enrichment and maintenance of cancer stem cells in head and neck squamous cell carcinoma |
| Q36553791 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. |
| Q34501607 | Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer |
| Q89030653 | ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition |
| Q52692152 | Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. |
| Q88497994 | Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies |
| Q91981735 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials |
| Q38800617 | Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model |
| Q38943518 | Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition |
| Q50251062 | Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance |
| Q55457412 | Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. |
| Q98159763 | Genetic analysis in the clinical management of biliary tract cancer |
| Q92889997 | Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma |
| Q54110583 | Hey1- and p53-dependent TrkC proapoptotic activity controls neuroblastoma growth. |
| Q96302702 | Histology-agnostic drug development - considering issues beyond the tissue |
| Q91710508 | How I treat NTRK gene fusion-positive cancers |
| Q36066539 | Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer |
| Q51040335 | Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms. |
| Q64052462 | Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications |
| Q30235979 | Implementing Genome-Driven Oncology |
| Q38618205 | Implications of mitogen-activated protein kinase signaling in glioma. |
| Q46044924 | Infantile NTRK-associated Mesenchymal Tumors. |
| Q54117764 | Inhibiting TRK Proteins in Clinical Cancer Therapy. |
| Q57154788 | Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application |
| Q52723930 | Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. |
| Q92891966 | Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion |
| Q38812870 | LY294002 induces in vitro apoptosis and overexpression of p75NTR in human uterine leiomyosarcoma HTB 114 cells. |
| Q64271812 | Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study |
| Q40502136 | Low brain-derived neurotrophic factor levels are associated with active disease and poor prognosis in childhood acute leukemia. |
| Q54981810 | Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors. |
| Q92924197 | NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target |
| Q92377719 | NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls |
| Q58547264 | NTRK fusion-positive cancers and TRK inhibitor therapy |
| Q28066821 | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types |
| Q89916769 | NTRK gene fusions: a rough diamond ready to sparkle |
| Q91620740 | NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases |
| Q92142969 | NTRK testing: first results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays |
| Q36629492 | NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line |
| Q51252178 | Nerve Growth Factor Promotes Gastric Tumorigenesis through Aberrant Cholinergic Signaling. |
| Q52639269 | Neuroblastoma: clinical and biological approach to risk stratification and treatment. |
| Q50201584 | Neurotrophin Trk Receptors: New Targets for Cancer Therapy |
| Q64117104 | Neurotrophin receptor tyrosine kinases regulated with near-infrared light |
| Q61796841 | Neurotrophins and their involvement in digestive cancers |
| Q89151574 | Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies |
| Q52885342 | Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. |
| Q41487925 | Paired Expression Analysis of Tumor Cell Surface Antigens |
| Q90275490 | Pediatric low-grade glioma in the era of molecular diagnostics |
| Q99237681 | Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors |
| Q26774478 | Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging |
| Q91828934 | Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer |
| Q41631541 | Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors |
| Q64237933 | Refractory and metastatic infantile fibrosarcoma harboring fusion shows complete and durable response to crizotinib |
| Q92578812 | Resistance to TRK inhibition mediated by convergent MAPK pathway activation |
| Q90262410 | Revisiting NTRKs as an emerging oncogene in hematological malignancies |
| Q41636361 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). |
| Q90224381 | Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential |
| Q38780383 | Small Molecules for Active Targeting in Cancer |
| Q33899971 | Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target. |
| Q52321854 | Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. |
| Q37690917 | Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy |
| Q37599025 | Structural characterization of nonactive site, TrkA-selective kinase inhibitors. |
| Q57943504 | Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma |
| Q59809201 | Syntaxin-1/TI-VAMP SNAREs interact with Trk receptors and are required for neurotrophin-dependent outgrowth |
| Q90344235 | Systemic therapy in pediatric-type soft-tissue sarcoma |
| Q57050736 | TRK Inhibition: A New Tumor-Agnostic Treatment Strategy |
| Q54977240 | TRKB tyrosine kinase receptor is a potential therapeutic target for poorly differentiated oral squamous cell carcinoma. |
| Q38371672 | Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q38819055 | Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence |
| Q91897087 | Testing algorithm for identification of patients with TRK fusion cancer |
| Q91826180 | The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response |
| Q99591067 | The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer |
| Q54978149 | The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung. |
| Q55422121 | The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII. |
| Q35889315 | Tracking Down Response and Resistance to TRK Inhibitors |
| Q89683301 | Transposon Insertion Mutagenesis in Mice for Modeling Human Cancers: Critical Insights Gained and New Opportunities |
| Q50321745 | TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation |
| Q37419153 | Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy |
| Q39166795 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I. |
| Q39166808 | Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II. |
| Q90664041 | Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion |
| Q36073551 | Tyrosine receptor kinase B is a drug target in astrocytomas |
| Q34514469 | What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). |
Search more.